Information updates

PBS listing of RINVOQ® (upadacitinib) for severe atopic dermatitis

AbbVie announced on 22 January 2022 that RINVOQ® (upadacitinib), a Janus Kinase 1 (JAK1) inhibitor, has been listed on the Pharmaceutical Benefits Scheme (PBS) for Australian patients living with severe atopic dermatitis (eczema), which can affect their whole body, face or hands.

Atopic dermatitis is a chronic inflammatory skin condition caused by an overactive immune system and is one of the most common and severe forms of eczema. Approximately 1.6 million Australians are thought to be living with atopic dermatitis, with around one in five of these suffering from a moderate to severe form of the condition.

Atopic dermatitis has a significant impact on quality of life.  As there is no cure for atopic dermatitis, the main goals in managing the disease are to reduce itch, minimise rash, and limit the impact on quality of life. Access to targeted therapies such as RINVOQ® (upadacitinib) provides additional treatment options to help alleviate the burden of this chronic condition. 

More information:

This news item was issued on 1 February 2022 by the Australasian Society of Clinical Immunology and Allergy (ASCIA), the peak professional body for clinical immunology and allergy in Australia and New Zealand.

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia